CD33 and acute myeloid leukemia: To generate a therapeutic outcome for AML, it will be necessary to engineer the anti-CD33 Nbs into BiTE or CAR-T cell constructs, or to decorate them with toxic drugs into ADC or with radionuclides for TRNT.